Additionally, inspired by the recent DCAT Lugano summit, we will include a dedicated segment on patient centricity—exploring how industry stakeholders are working to place patients at the heart of drug development, manufacturing, and delivery. Whether you have a unique perspective on pharmaceutical innovations, sustainable practices, regulatory updates, or emerging trends in nutraceuticals and personal care, we welcome your submissions for editorials. This is an opportunity to engage with a diverse readership and contribute to the collective knowledge of our field. As we launch this dynamic issue at CPHI Frankfurt, we are excited to foster connections and discussions that will empower our community. For submission guidelines and further information, please visit our website or contact our editorial team. Together, we’re shaping the future of chemicals — smarter, sustainable, and more connected than ever before. ELLIE BRUNI Publishing Director CHEMICALS KNOWLEDGE HUB As the official media partner for CPHI Frankfurt, we are thrilled to announce the launch of our new dynamic issue of the Chemicals Knowledge Hub, a publication dedicated to advancing knowledge and fostering dialogue across the chemical industry. Collaborating for the future with new event partnerships We believe that real connections lead to real progress. That’s why we’re forming partnerships with upcoming industry events, which will allow us to bring you exclusive coverage, updates from expert speakers, and opportunities to network with leaders and innovators from around the world. It’s all about creating a community where ideas can flow, and collaborations can flourish. Looking ahead Our goal is simple: to make knowledge accessible, engaging, and useful for everyone involved in the chemical industry. With fresh content, innovative delivery, and strong partnerships, we’re dedicated to supporting your journey — whether you’re exploring new markets, developing cutting-edge products, or just staying informed. This issue will spotlight the pharmaceutical sector while also encompassing a broader spectrum of topics, including corporate responsibility, regulatory, nutraceuticals, personal care, cosmetics, and beyond. Publishing Director: Ellie Bruni | +44 (0) 7872 516194 ellie.bruni@ckh.com Advertising: info@ckh.com Editorial contact: Please send your news and suggestions for feature articles to the editorial team at editor@ckh.com CHEMICALS KNOWLEDGE HUB is published by BIBO Publishing SL, Av. Diagonal, 409, 1St Floor, 08008, Barcelona, Spain. Disclaimer: The disclaimer has an error: BIBO Publishing SL will not be held responsible or liable for errors or omissions supplied or contained in this publication, although due care and attention are taken to ensure all content is accurate at the time of going to press. BIBO Publishing SL also will not be held responsible for any false claims made by advertisers, or in articles contributed by external authors. Copyright: The contents of this publication are copyright © BIBO Publishing SL 2025. No part of this publication can be reproduced or transmitted in any form without the express permission of the publisher. ISSN 2516-4482 WELCOME
2 CHEMICALS KNOWLEDGE HUB Issue 2 / October 2025 WELCOME 1 Fostering connections and innovation: Launching at CPHI Frankfurt ROUNDTABLE 24 Roundtable discusses marketing SUSTAINABILITY 32 Beyond greenwashing: Sustainability targets under pressure in pharma PROCOS 38 Embracing ESG with integrity: A legacy of responsibility CONTENTS 6 NEWS
3 CHEMICALS KNOWLEDGE HUB Issue 2 / October 2025 CONTENTS AGROCHEMICALS CONTRACT SERVICES CORPORATE RESPONSIBILITY COSMETICS & PERSONAL CARE DISTRIBUTION NUTRACEUTICALS MATERIAL SCIENCE OILFIELDS & ENERGIES PHARMACEUTICALS REGULATIONS & EHS&S WATER TREATMENT LIFE SCIENCES INDENA 40 Indena’s latest news in CDMO services CONTRACT SERVICES 44 Raising the bar: Pharma now demanding more from CDMO and CRO partnerships ROUNDTABLE 50 Insights and highlights: A roundtable discussion before CPHI DCAT SUMMIT SPECIAL 60 The DCAT Summit at Lugano - A recap REGULATORY 66 Pharma faces a new strategic battleground in regulation LIFE SCIENCES 70 Messenger RNA synthesis - An overview LEGENDA
6 CHEMICALS KNOWLEDGE HUB Issue 2 / October 2025 NEWS From the Amazon rainforest to laboratory benches, Lucas Meyer Cosmetics by Clariant is transforming the cosmetics industry with two sustainability milestones that blend environmental protection with community empowerment. The company is reinforcing its enduring commitment to responsible sourcing and environmental stewardship with ambitious new 2030 sustainability goals for its lecithin platform and the celebration of 25 years of the pioneering Beraca Socio-biodiversity Enhancement Program. Clariant is celebrating the 25th anniversary of the Beraca Sociobiodiversity Enhancement Program, a pioneering initiative that has been creating positive socio-biodiversity impact and empowering communities across Brazil for a quarter century. Since acquiring Beraca in 2021, Clariant has continued to strengthen this program, which now operates in 11 Brazilian states and 36 communities, supporting approximately 14,000 families. “The Beraca Socio-Biodiversity Enhancement Program exemplifies how business success and environmental protection can work hand in hand,» said Flavia Igreja, Product Line Manager for Beraca at Clariant. «After 25 years, this initiative continues to demonstrate that economic empowerment is fundamental to conservation efforts.” The program has created sustainable economic opportunities for local populations by providing alternative income sources that reduce reliance on deforestationrelated activities. This approach has successfully bridged local communities with global markets while conserving Brazil›s rich biodiversity. The 25th anniversary of this groundbreaking program will be highlighted at in-cosmetics Latam in late September 2025. At the same time the new sustainability strategy for Lucas Meyer Cosmetics› lecithin platform builds on 25 years of expertise in cosmetic ingredients derived from lecithin. By 2030 the business has committed to offering 100% soy-based derivatives from guaranteed nonGMO soy and ensuring at least 80% of its soy-lecithin-based ingredients are obtained from responsibly sourced soy backed with 3rd party certification. Critically, the initiative also includes a zero-deforestation commitment, striving to ensure the entire soy supply chain originates from areas where forests remain protected. “This commitment represents a significant step forward in our sustainability and lecithin platform journeys”, said Isabelle Lacasse, Head of Global Marketing, Product Line Management & Formulation at Lucas Meyer cosmetics by Clariant. “We›ve already adapted our production and supply chains capacities to achieve this objective, demonstrating our dedication Lucas Meyer Cosmetics advances sustainability with dual milestone achievements
7 CHEMICALS KNOWLEDGE HUB Issue 2 / October 2025 NEWS to raising industry standards”. The lecithin platform strategy focuses on enhancing supply chain transparency and traceability while systematically reducing environmental and social risks. Lucas Meyer Cosmetics and its suppliers are committing to responsible practices and encouraging thirdparty certifications such as ProTerra. This initiative builds on Clariant›s broader supplier engagement program, which for example includes the membership in the Action for Sustainable Derivatives (ASD). Lucas Meyer Cosmetics› lecithin expertise spans both functional and active ingredients, supported by a specialized formulation team that helps customers successfully incorporate these responsibly sourced ingredients into their products. This technical expertise, combined with the company›s sustainability commitments, positions Clariant as a leader in responsible cosmetic ingredient sourcing. These dual initiatives underscore Clariant›s ongoing commitment to sustainability as a core strategic pillar, continuously improving processes and sourcing practices to deliver cosmetic ingredients that exceed industry standards for responsible and ethical sourcing. By focusing on both environmental protection and community empowerment, Clariant demonstrates that meaningful sustainability requires a comprehensive approach that addresses both ecological and social dimensions. Visitors to in-cosmetics Latin America 2025 can learn more about Beraca and the programs firsthand at booth no. L 30. Beraca™ IS A TRADEMARK OF CLARIANT. Charged with accelerating the next generation of green innovation Inolex has appointed Miao Wang as its new Vice President of Research, Development, and Commercialization. Wang, who has led global teams at L’Oréal and Dow Chemical, will focus on advancing Inolex’s green chemistry platform and driving the next generation of sustainable ingredient innovation for beauty and personal care customers worldwide. “Miao is a highly accomplished scientist and strategic business leader with a keen ability to bring bold, transformative projects to life,” said Art Knox, President. “She has a talent for building a strong R&D pipeline, from ideation through end-to-end product development, and for creating an innovation roadmap that accelerates speed-to-market.” Wang previously led L›Oréal’s Green Science Acceleration, a global initiative to accelerate green science transformation to address decarbonization and build a resilient feedstock strategy. She also led the ingredients innovation team in the US to deliver high-performing, disruptive technologies for global product launches. Her influence runs broad and deep across the industry. She is credited with several high-profile brand launches and has a reputation for identifying and capitalizing on white space opportunities. “In many ways, ingredient design is an engine that defines sustainable innovation and enables the claims that consumers desire,” explains JeanMarc Dumontier, Head of R&D, Ambi Enterprises. “Miao approaches collaboration by listening to the customer and bridging opportunities to deliver meaningful advancements in safety, sustainability, and performance.” Wang steps into the role at a pivotal moment in the company’s growth, as Inolex leans into its strategic customer partnerships and collaborative business efforts to address emerging industry shifts. “It’s an honor to have Miao lead the next phase of sustainable ingredient innovation, and we can’t wait to see the impact of her leadership,” added Knox. Inolex names Miao Wang as Vice President of Research, Development, and Commercialization
8 CHEMICALS KNOWLEDGE HUB Issue 2 / October 2025 Landmark investment aligns with Thailand 4.0 strategy, driving exports, jobs, and health innovation Sirio Pharma, the world’s largest contract developer and manufacturer of nutraceuticals, today announced the start of construction on its first manufacturing site in Thailand, as well as its first Asian facility outside China. The $40 million state-of-theart site in Chonburi will cover approximately 60,000 sqm and is expected to be fully operational by 2027. The new smart factory will be among the most advanced nutraceutical facilities globally, integrating automated production lines, robotics, AI-driven process controls, and sustainable energy systems. This investment represents a major step forward in Thailand’s 4.0 strategy, strengthening the nation’s reputation as a hub for high-value, high-tech manufacturing and enhancing its export competitiveness in the fast-growing global nutraceutical market. Beyond infrastructure, the project will create high-skilled local jobs in manufacturing, quality, and R&D, while providing training in advanced production technologies. The site will also serve as a center of collaboration with Thai universities and local suppliers, supporting innovation across the country’s health and wellness sector. “This investment is not just about a new factory — it is about creating a long-term partnership with Thailand,” said Alex Du, General Manager, Asia Pacific BU at Sirio Pharma. “Thailand offers exceptional talent, advanced infrastructure, and a strategic location in the heart of Southeast Asia. Our Chonburi site will be one of the most advanced nutraceutical plants globally — featuring smart factory technologies, integrated R&D capabilities, and our proprietary formulation platforms. Together with local partners, we aim to help position Thailand as the leading regional hub for health and nutrition innovation, boosting exports and giving Thai brands a platform to reach global markets.” The facility will supply both domestic and international customers, contributing to Thailand’s net trade surplus and supporting the country’s ambition to become a regional leader in wellness and functional foods. Sirio currently operates seven facilities worldwide – in the EU, USA, and China – making Chonburi its eighth global site. This expansion strengthens the company’s ability to offer localized production and faster time-tomarket, especially for customers in Southeast Asia where demand for nutraceuticals has surged — with Sirio’s APAC revenues (excluding China) growing 77% year-on-year. The project will be formally unveiled during Vitafoods Asia in Bangkok, where Sirio will also host its first APAC Future Forum, bringing together over 150 industry stakeholders to discuss growth opportunities and strategies to help Thai brands expand internationally. NEWS Sirio Pharma invests $40M in first thai manufacturing site to Thailand’s role as a global nutraceutical hub
10 CHEMICALS KNOWLEDGE HUB Issue 2 / October 2025 Axplora initiates global investments exceeding €100m in 2025 NEWS Axplora, a global leader in small molecule API manufacturing and a trusted partner to the world’s most innovative pharmaceutical companies, today announced that the total investments initiated across its global network in 2025 will exceed €100 million. This commitment underscores Axplora’s determination to accelerate growth, strengthen capabilities, and reinforce its position at the forefront of pharmaceutical manufacturing worldwide. The total includes the increased amount of €60 million allocated to the ongoing expansion of its Mourenx, France site, alongside €35 million at Gropello, Italy, and €8.5 million at Vizag, India, both announced earlier this year. In addition, March this year saw the expansion of Axplora’s ADC (antibody-drug conjugate) manufacturing capabilities at is site in Le Mans, France. Strengthening capacity, capability and delivery These projects extend across several years, embedding long-term capability across the business. The scale of the Mourenx initiative, in particular, is giving Axplora’s teams the opportunity to expand expertise and set new benchmarks of excellence through close collaboration with a customer on a project of significant size and complexity. Insights and best practices developed there are now being shared across Axplora’s nine global sites, strengthening a culture of continuous improvement and ensuring every site is equipped to deliver best-in-class execution with reliability, speed, and efficiency. While new modalities such as GLP-1 peptides and ADCs stand out as high-growth opportunities, small molecules remain the foundation of global pharmaceutical manufacturing, accounting for the majority of prescriptions today and well into the future. Axplora’s €100m investment program reflects this balance: reinforcing large-scale small molecule capacity, while also expanding in highgrowth, high-complexity areas. By investing across modalities, Axplora is ensuring resilience and reliability for the essential medicines patients depend on today, and readiness for the advanced therapies that will define tomorrow. Martin Meeson, CEO of Axplora, commented: “Announcing €100 million of investment this year is a landmark for Axplora – but more than just a number, it represents the trust our customers place in us and the scale of our commitment to them and their patients. Each euro invested is directed towards strengthening our capabilities, expanding our global network, and ensuring we are prepared to deliver the next generation of medicines with speed and reliability.” Arul Ramadurai, CCO of Axplora, added: “These investments reflect the trust our customers place in us and our commitment to working side by side with them. At Axplora, we dare to imagine a future where no patient waits for the medicines they need. That vision drives us to understand our customers’ needs better than anyone else, and to build the scale, expertise, and capabilities that will help bring their breakthroughs to life faster and more efficiently.” Symeres appoints Gabriella Gentile as Chief Operating Officer to drive transatlantic growth Gabriella brings more than 25 years of international experience in the pharmaceutical, medical device, and services industries. She has held senior roles at Catalent, Roche and Aptuit, where she led major transformation programs focused on operational performance, lean methodologies, and change management. In her new role, Gabriella will lead the transformation of global operations at Symeres, focusing on expanding capabilities across the pharmaceutical value chain from inception to investigational new drug (IND). She will apply her proven leadership to align business operations with measurable performance outcomes, reinforcing Symeres’ commitment to quality and customer satisfaction. “I’m delighted to join Symeres at this exciting time in their growth,” said Gabriella Gentile, “Symeres operates under a cultural philosophy of openness
11 CHEMICALS KNOWLEDGE HUB Issue 2 / October 2025 Sunresin New Materials Co., Ltd. has announced plans to invest USD 160 million in the construction of a HighEnd Life Science Advanced Materials Industrial Park in the Pucheng High-Tech Industrial Development Zone, China. The project will span approximately 18 hectares and serve as a flagship facility for the development and large-scale production of critical bioprocessing materials, including: - Agarose and polymeric chromatography media - Enzyme carriers - Resins for oligonucleotide and peptide solid phase synthesis - Adsorption resins and separation materials - GMP facility for manufacturing APIs and excipients - Resins for ultrapure water production - Food- and biopharma-grade resins - Chromatographic equipment This investment highlights Sunresin’s strategy to grow its life sciences business, meet the increasing global demand for downstream processing solutions, and solidify its standing as a leading innovator in the field. “The creation of this new industrial park reflects Sunresin’s confidence in the long-term growth of the life sciences sector,” said Dr. Ivy Gao, CEO of Sunresin. “By expanding our capacity and capabilities, including a new GMP facility for the manufacturing of APIs and excipients, we aim to provide the global biopharmaceutical industry with more reliable, high-performance chromatography resins and separation technologies.” Although the initiative may not affect financial performance immediately, it positions Sunresin to take advantage of emerging opportunities in biopharmaceuticals, advanced therapies, and global downstream processing. According to the company, land acquisition will take place through a public auction, and construction and development are subject to the usual regulatory approvals. NEWS Sunresin announces USD 160 million investment to build state-of-the-art life sciences industrial park in Pucheng and transparency, and I look forward to being part of developing new next generation therapies”. She added, “I am ambitious in my expectations of how my global operational experience can positively impact Symeres’ growth targets and I’m committed to delivering outstanding customer experiences. Symeres’ growth trajectory makes this an exciting time to join.” Guillaume Jetten, Symeres CEO, added “I’m delighted that Gabriella has accepted this position. ‘Gabriella brings a set of highly relevant skills and experience from both her background in medicinal chemistry, but also her decades of large Pharma and biotech experience that will support the future growth plans of Symeres”. Most recently, Gabriella served as global improvement director at Catalent, where she developed and implemented standardized operational frameworks across multiple sites. Prior to that, she consulted independently on global change and operational excellence programs, helping organizations improve performance and implement strategic business initiatives. Her appointment marks another significant step in Symeres’ expansion strategy, as the company positions itself as a global biotechnology leader bridging European innovation and American market presence.
14 CHEMICALS KNOWLEDGE HUB Issue 2 / October 2025 NEWS GELITA to present breakthrough softgel and bioscience excipients at CPHI Frankfurt 2025 As the recognized expert for softgel gelatin and collagenbased excipients, GELITA offers specialized solutions designed to meet today’s most demanding industry needs. The Softgel Specialty Portfolio includes solutions for revolutionary rapid fill release, enabling true enteric soft capsules, leaking prevention or avoiding cross-linking. These solutions offer pharma companies greater flexibility in formulation and improved stability for sensitive ingredients. Endotoxin Controlled Excipients for Bioscience Applications are specifically developed for advanced uses in vaccine stabilization, 3D bioprinting, regenerative medicine, and medical devices. With stringent endotoxin control, these excipients support maximum safety and efficacy, opening up new pathways in drug delivery and biomedical engineering. Visitors to GELITA’s booth will not only discover these innovations but also benefit from direct engagement with experts from the GELITA Pharma Institute, who will be available for one-on-one consultations to help tailor solutions to individual project challenges. As part of the program, GELITA is also hosting a scientific lecture: Title: The Role of Non-Animal Recombinant Collagen Proteins in Biomedical Applications: From Vaccine Stabilization to Artificial Organs Date & Time: Tuesday, October 28, 2025, at 1:30 PM With its pioneering developments in softgel and bioscience excipients, GELITA is setting new standards in product performance, safety, and innovation. Don’t miss the opportunity to meet the leaders in excipient innovation at CPHI Frankfurt 2025 – Booth 3.0D37. Beyond Carnauba: Clariant’s reliable bio-based wax for resilient printing inks and premium applications How can you achieve flawless aesthetics and high-performance functionality in inks and coatings while meeting the world’s demands for greater sustainability, transparency and supply chain resilience? For decades, carnauba wax and its blends, often combined with polymers, have been the trusted choice for delivering high-quality finishes in printing inks and packaging. However, as a natural, seasonal material, carnauba wax is subject to unpredictable supply fluctuations that are increasingly challenging production schedules, particularly in the US market where tariffs are further exacerbating availability and costs. The pressure is now on manufacturers and formulators to urgently find reliable, highperforming and sustainable alternatives. This growing uncertainty is driving a wave of innovation, unlocking new
15 CHEMICALS KNOWLEDGE HUB Issue 2 / October 2025 NEWS bio-based solutions that meet performance demands while reducing environmental impact and sourcing risk. Advancing wax technology with rice bran wax compound This market situation highlights the critical importance of reliable, high-quality, bio-based alternatives such as Ceridust™ 1310, which can help businesses maintain performance and continuity amid economic and regulatory pressures. Ceridust 1310, a biobased wax compound, that comes in the form of micronized rice bran wax and achieves a melting point of over 120°C and excellent rub resistance. It encourages the potential of rice bran wax to offer greater consistency, and Clariant is working to strengthen this further. “It’s about expanding formulation options with a reliable, bio-based alternative to help ensure consistent quality despite market fluctuations,” explains Simon Bodendorfer, Application Development Manager of Coatings and Inks. From field to formulation Ceridust 1310 is a highperformance wax additive based on a carefully selected blend that includes rice bran wax: a renewable, non-food-competing byproduct of agriculture. Designed to meet modern formulation needs, it offers a reliable combination of sustainability, consistency, and process efficiency, helping formulators reduce variability and enhance the environmental profile of coatings and inks. Ceridust 1310 ensures stable, batch-to-batch quality that supports consistent performance and minimizes material waste. With its renewable content, it contributes to reducing reliance on fossil-based materials. Applications across premium printing and packaging The versatility of these new wax technologies makes them suitable for many high-end uses where appearance and performance matter: - Premium packaging with matte finishes The matting properties create the elegant, understated look luxury brands expect. Consistent quality ensures packaging meets strict standards across batches. - Glossy magazines For publications that demand sharp images and durability, these additives offer excellent rub resistance at low doses (0.2–1%), protecting vibrant visuals while keeping production efficient. - Specialty labels Labels need to withstand handling, shipping, and various environments while staying visually appealing. Advanced waxes provide durability without sacrificing look. - Water-based topcoats As the industry shifts toward water-based systems, these waxes perform well in formulas that require strong scuff resistance and clarity. Easy to formulate, easier to adopt Transitioning to new additives doesn’t have to mean reworking entire formulations or disrupting production. Ceridust 1310 is designed for easy integration. It works effectively in common systems at low dosage levels (0.2– 1% for printing inks and up to 4% for coatings). Its compatibility allows formulators to adopt it gradually, replacing carnauba or synthetic waxes without significant changes to existing processes while gaining flexibility and sustainability benefits. What’s next? Bio-based wax additives are part of a bigger shift in the industry. Rather than simply replacing old ingredients with new ones, Clariant is continuously developing smarter solutions that perform well, are more sustainable than fossil-based alternatives and can be produced on a large scale. For formulators seeking control, supply security and stronger environmental alignment, the future isn’t about compromise; it’s about achieving greater chemistry. You can access the audio version of the blog at the official website of Clariant. Ceridust™ IS A TRADEMARK OF CLARIANT.
16 CHEMICALS KNOWLEDGE HUB Issue 2 / October 2025 Labomar acquires Finnish company Pharmia, strengthening its position in Northern Europe NEWS Labomar S.p.A., a leading international nutraceutical company specialising in the research, development, and contract manufacturing of dietary supplements, medical devices, foods for special medical purposes, and cosmetics, announces the acquisition of 97.85% of the share capital of Pharmia Holding Oy, Finland’s leading CDMO (Contract Development and Manufacturing Organisation). Pharmia specialises in the development and production of dietary supplements, probiotics and medical devices. Labomar is backed by leading European private equity firm Charterhouse Capital Partners. Founded in 1993, Pharmia now employs 85 people at its headquarters in Tuusula, just a few kilometres from Helsinki Airport, and operates a 5,000 m² integrated production site with an annual capacity of approx. 485 million tablets and capsules, and 37,000 litres of liquids. With 2024 turnover of €20 million, further visible growth in 2025, a leading position in the Nordic countries (Finland, Sweden, Denmark and Norway) and extensive expertise in the development of probiotics and medical devices, the company consistently invests 5% of its turnover in research and development, continuing to strengthen operational efficiency and confirming itself as a strategic partner for numerous international players. The transaction is Labomar Group’s fifth acquisition in six years, highlighting the company’s growth strategy, which has always been focused on innovation, the development of advanced health solutions and a diversified global presence. The acquisition of Pharmia Holding Oy will enable the company to continue to expand its expertise in research and development, particularly in medical devices and probiotics, and to benefit from a central position in a highpotential region, which has estimated* CAGR growth of 5-7% over the 2024-2029 period. Expanding into the Nordic market will also enable Labomar to consolidate its international presence in nutraceuticals and medical devices, expanding its customer base and generating new synergies in terms of innovation and product development. The transaction was finalised on September 25, with Pharmia’s current management remaining within the company and continuing to hold 2.15% of the company’s capital. “Welcoming Pharmia into our Group is a source of great satisfaction and represents a key step in our vision for international growth,” stated Walter Bertin, founder and Chief Executive Officer of Labomar. “We have found a team that shares our approach to innovation and quality, allowing us to strengthen in a market full of opportunities, in which we can build lasting relationships with major players and accompany them in attaining increasingly advanced solutions. In addition, Pharmia’s solid management structure and production capacity will enable us to rapidly integrate activities and accelerate the development trajectory we are charting at a panEuropean level”. Antonio Di Lorenzo, Partner at Charterhouse Capital Partners, added, “We are very pleased to have supported the continued growth of Labomar over the past few years, both through organic expansion and through M&A opportunities, a key pillar of our value creation strategy.” Petteri Laaksomo, CEO of Pharmia Holding Oy, commented, “We are thrilled to be part of the Labomar family. This acquisition marks a strategic step forward in our mission to expand our footprint in the Nordic region and strengthen our capabilities in the development of high-quality nutraceuticals and medical devices. Labomar’s expertise and values align seamlessly with ours, and together we look forward to driving innovation and delivering even greater value to our partners and customers”. Labomar continues to pursue its acquisition-led growth strategy which begun in 2019, supported by Charterhouse Capital Partners and its value-creation capabilities, with the acquisition of Importfab (now Labomar Canada), which operates in the North American pharmaceutical, cosmetic and nutraceutical market; in 2020 with the entry of the Welcare Group, based in Orvieto (Umbria) and specialising in medical devices for the prevention, hygiene and
17 CHEMICALS KNOWLEDGE HUB Issue 2 / October 2025 NEWS treatment of skin infections and lesions; of Labiotre, located in Tavarnelle Val di Pesa (Tuscany) and dedicated to the production of plant extracts and softgel dietary supplements; and finally of Laboratorios Entema, a Barcelonabased company specialising in the contract manufacturing of cosmetics, medical devices and dietary supplements. The acquisition transaction was coordinated by an internal team comprising Claudio De Nadai (Board Member), Marco Malaguti (Chief Strategy Officer) and Nicola Tomasini (Group Chief Financial Officer). Labomar was assisted in the acquisition by BModel as Corporate Advisor, which coordinated the professional activities dedicated to Business Due Diligence, carried out by Boston Consulting Group, for the Financial & Tax Due Diligence by EY Epyon, in addition to Legal Due Diligence, and the drafting of the legal and contractual documents by PwC Legal. *Boston Consulting Group report Clariant has unveiled HAIRMONIST: The Hair Symphony, a new hair care concept that harmonizes personalization, sustainability, and sensory experiences to meet evolving consumer demands. Developed by Clariant›s Latin American team, this new approach demonstrates how the company›s specialized ingredients enable beauty brands to create customized hair care solutions. The HAIRMONIST concept addresses the growing consumer desire for personalized beauty experiences that combines individual values and needs. With Clariant’s extensive portfolio of ingredients with a high share of renewable content, formulators can now develop tailored hair care products that deliver both exceptional performance and environmental responsibility. One example in this range is Plantasens™ Olive LD & SP ECO which serves as natural alternatives to silicones. “Today›s consumers expect hair care products that are as unique as they are,“ said Diana Gaitan, Marketing Manager Personal & Home Care at Clariant. “With HAIRMONIST, we are showcasing how our ingredients can be orchestrated to create personalized formulations that deliver outstanding performance and answer the growing demand for natural beauty solutions. Beyond functionality, this concept embodies our commitment to helping brands design products that forge a deeper emotional connection with consumers.“ At the heart of the HAIRMONIST concept is Clariant›s comprehensive range of renewable-based ingredients, including the GlucoTain line of mild surfactants, which offers excellent cleansing properties while maintaining the natural moisture balance of hair and scalp. The Genadvance line provides targeted conditioning and protection benefits that can be customized to address specific hair types and concerns, from damage repair to color protection. “The versatility of these ingredient systems allows especially regional formulators in Latin America to create products for diverse hair types and concerns. Innovative combinations of Aristoflex™ and Genadvance create unique sensory experiences that enhance the emotional connection between consumers and their hair care routines, transforming daily hair care into moments of wellness,“ explained Luciana Rodrigues, Head of Application Development Personal Care at Clariant, Americas. ™ ARE TRADEMARKS OF CLARIANT. Clariant’s HAIRMONIST concept - a new way for personalized hair care formulations
18 CHEMICALS KNOWLEDGE HUB Issue 2 / October 2025 Bioiberica celebrates its 50th Anniversary at CPHI 2025 by highlighting its legacy in Heparin API, a new brand identity and long-term investment in scientific research NEWS Bioiberica, a global life sciences company, is set to celebrate its 50th anniversary at CPHI Worldwide 2025 with a significant milestone: the launch of a renewed brand identity and new website, which are a tribute to our past and a reflection of our commitment to innovation and leadership in the industry. As part of this forward-looking approach, the company is actively exploring new applications for life-saving heparin molecules through close collaboration with leading laboratories and research centres worldwide. This strategic rebrand marks the culmination of half a century of dedication to advancing the health and well-being of people, animals and plants – which all started with the manufacture of the company’s world-reference Heparin API. The new branding presents a refreshed corporate purpose, “For a healthier, safer world”, and a revamped tagline, “We are all one”, showcased via the company’s new website. Heparin: where it all began Since its foundation in Palafolls (Barcelona) in 1975, Bioiberica has been a pioneer in the research, production and marketing of naturally sourced biomolecules, guided by the concept of “One Health”. The 50th anniversary commemorates five decades of leadership in the sector, driven by a collaborative approach to science and a commitment to sustainable, high-quality progress. At CPHI, Bioiberica will spotlight its position among the world’s leading producers of heparin – an essential antithrombotic molecule that saves more than 100 million lives a year. With unmatched expertise in this area, the company delivers tailored processes and formulations across its specialised Heparin portfolio, adapting to customers’ specific needs and applications. “As we look to the future, we continue to champion science and innovation to push the boundaries of heparin research, with more than 40 projects in research centres across 10 countries, working in partnership with esteemed institutions such as the G. Ronzoni Institute, King’s College London and other innovative medical technology firms,” comments Javier Velasco, R&D Director at Bioiberica. “This ongoing investment in research is vital to tackle global health challenges like thrombosis - which is estimated to cause 1 in 4 deaths worldwide - and advance complex projects from anticoagulant devices to next-generation ophthalmic treatments. Every year we increase our investment in R&D, enabling us to advance science and develop new molecules in collaboration with international strategic partners, affirming our position as a leading company in the advancement of life sciences on a global scale.” In addition to Heparin API, Bioiberica offers a wide portfolio of biologically derived APIs - including Thyroid, Chondroitin sulfate and Glucosamine. Visitors to booth 12.0D30 will also have the opportunity to explore Bioiberica’s flagship nutraceutical branded ingredients such as Collavant® n2 and Mobilee® for mobility, Dermial® for skin health and DAOgest® for histamine intolerance. Attendees can even be among the first to sample a pioneering ‘collagen milk’ featuring Collavant® n2, native (undenatured) type II collagen, at the “Coffee Corner” on stand. “We look forward to celebrating our 50th anniversary and sharing our refreshed visual identity with our partners at CPHI, as we begin the next chapter in our mission to drive the evolution of health” comments Luis Solera, CEO of Bioiberica. “The rebrand underscores our commitment to Life Science and the dedication of our team – comprised of over 500 professionals operating in nine global production centres – to deliver a portfolio of more than 100 products across a vertically integrated supply chain (as part of the SARIA Group) to over 80 countries. For 50 years, innovation has been our compass, and as we look to the future, we remain dedicated to advancing and shaping a healthier, safer world for all.” Quality and safety: a permanent commitment Quality and safety are inherent to Bioiberica’s history and to the manufacture of high-value ingredients of biological origin. The company ensures maximum traceability, quality and safety at every stage of product development thanks to the reliability of its processes and protocols developed over 50 years – including its unique circular economy model and vertical integration as part of the SARIA Group. This allows Bioiberica to deliver products of excellence that meet the most demanding standards in the pharmaceutical, veterinary, agricultural and nutraceutical sectors. The Bioiberica team can be found at booth 12.0D30 (zone API) at CPHI Worldwide 2025, Messe, Frankfurt, from 28-30 October 2025. To learn more, visit: www.bioiberica.com
20 CHEMICALS KNOWLEDGE HUB Issue 2 / October 2025 NEWS Join AB-BIOTICS at CPHI 2025 for an exclusive look at its latest advanced biotic solutions for specific health indications across the lifespan. Visitors can explore innovative product line debuts, cutting-edge clinical data and new science-backed probiotic strains that empower pharma brands to deliver unique, tailored solutions with real impact. Make sure you visit stand 3.0A68 to unlock: - Expertly tailored probiotics that care for growing lives – AB-BIOTICS will introduce its Pediacare line of biotic solutions targeting a range of health indications from infancy to adolescence. The portfolio features precision strains and blends that support gut health, skin health, immunity and cognition — backed by age-specific trials. Visitors can also learn about ongoing and soon-to-be published trials set to further strengthen the offering. - The unveiling of AB-BIOTICS’ newest therapeutic area - healthy ageing. The portfolio will include two products with freshly published clinical data, including its INNERIM® blend, which was seen to reduce constipation in adults over 50 years old and has the potential to support mental wellbeing. The portfolio will also include Latilactobacillus sakei LB-P12, a probiotic with pre-clinical and clinical evidence showing it supports joint pain and osteoarthritis. - The expansion of the company’s Gyntima® product line for women’s health - including a new product, Gyntima® Iron, with published evidence on addressing iron deficiency due to menstruation. AB-BIOTICS will also be spotlighting Gyntima® Balance, consisting of strain Lactobacillus gasseri KABP®- 064. A recent study revealed that it colonizes the vaginal microbiota of healthy women after oral administration, with the potential to promote vaginal health. - Advanced postbiotic solutions for medical device applications – the team will be showcasing innovative solutions including Gyntima® Restore for vaginal health, AB-Protears® to address dry eyes, allergies and ocular inflammation, and LipiGO® to support weight management. Discover the science behind ABBIOTICS’ leading biotics innovations, and how a precision approach is defining biotic innovation at CPHI 2025. Discover cutting-edge biotics innovation with AB-BIOTICS at CPHI 2025 – stand 3.0A68
21 CHEMICALS KNOWLEDGE HUB Issue 2 / October 2025 NEWS
22 CHEMICALS KNOWLEDGE HUB Issue 2 / October 2025 NEWS Quotient Sciences, a leading global drug development, research and manufacturing accelerator, and Biorasi, a global clinical research organization (CRO), today announced a strategic partnership to deliver fully integrated early phase clinical trial solutions. The partnership will combine Quotient Sciences’ expertise in early clinical development with Biorasi’s global patient recruitment capabilities to provide biotech and pharma Sponsors with a simplified, efficient pathway from Investigational New Drug (IND) to proof-of-concept (POC) with seamless transitions from healthy volunteers into patient groups within first-in-human (FIH) Phase I/IIa clinical trials. Sponsors will benefit from Quotient Sciences’ clinical pharmacology expertise, with facilities in Miami (US) and Nottingham (UK) comprising 230 beds and supported by a large database of trial participants. This is complemented by Biorasi’s global patient recruitment network, which spans a wide range of therapeutic areas including dermatology, neurology, nephrology, cell therapy, and other specialty fields. The partnership will provide sponsors with a single provider model for FIH to POC programs, with the option of a single contract and a unified protocol and regulatory submissions to reduce the outsourcing complexity and accelerate development timelines. Quotient Sciences is a recognized leader in early clinical development, with deep expertise in Phase I healthy volunteer studies and early patient proof-ofconcept (POC) trials. Quotient Sciences and Biorasi partner to accelerate early phase clinical trials to patient proof-of-concept
23 CHEMICALS KNOWLEDGE HUB Issue 2 / October 2025 NEWS To meet growing industry demand for patient assessments and biomarker integration in first-inhuman (FIH) studies, the company is expanding its patient access framework through a network of academic and commercial collaborators. These hybrid or multi-part protocols—combining healthy volunteer and patient cohorts within a single integrated design— offer speed, flexibility, and scientific rigor and a seamless pathway for generating early clinical data. Thierry Van Nieuwenhove, CEO of Quotient Sciences, commented: “This partnership reflects our 35-year commitment to helping customers accelerate drug development to Proof of Concept by reducing complexity and breaking down traditional barriers. By combining Quotient’s clinical expertise with Biorasi’s global patient access network, we enable Sponsors to efficiently conduct early-phase studies under a single operational and contracting model, while maintaining the highest standards of clinical research and data quality. We take your molecule to the next stage of its journey— faster and more cost-effectively than anyone else.” “Biotech and pharma innovators need flexible, reliable solutions to succeed in today’s evolving clinical trial environment,” added Chris O’Brien, CEO of Biorasi. “Through this collaboration with Quotient Sciences, we are providing Sponsors with a simplified, scalable model that supports everything from FIH studies to patient POC, helping new therapies reach patients faster.” The expansion into patients is a natural extension of Translational Pharmaceutics®, Quotient’s disruptive approach to drug development which seamlessly integrates formulation development, drug product manufacturing, and clinical testing, saving up to 12 months and accelerating data-driven decision making. The venture also expands opportunities for adjacent services including comprehensive CDMO offerings such as pharmacy compounding, drug product manufacturing, data sciences, and regulatory support.
24 CHEMICALS KNOWLEDGE HUB Issue 2 / October 2025 What are your top tips for CDMOs or other suppliers attending CPHI – how should they go about planning? AH. My top tip is to treat CPHI as the ‘cherry on top’ of your year-round brand-building efforts – not a oneoff spending spree. Many CDMOs focus on ‘going big’ at the event, but this only works if it reinforces a consistent message. Plan annually and map out your communications journey, aligning marketing with your business development team, so your messaging supports their outreach. We typically work with an annual mapped plan, but supported by rolling three-month deliverables, which lead into key industry moments like JPM, DCAT, BIO and CPHI. This approach ensures your brand presence crescendos at the right time to drive new business. Another key tip: make your direct outreach, webinars and PR genuinely engaging and trend based in the ROUNDTABLE Five executives were recently interviewed on the value of marketing/public relations at CPHI events. They were: Alex Heeley (AH), Managing Partner, De Facto Communications; Raman Sehgal (RS), host of Molecule to Market; Tara Dougal (TD), Event Director, CPHI Europe; Emily Snipe (ES), Account Director, Notch Communications and Olivia Addinall (OA), Head of Client Services, Ramarketing. ALEX HEELEY Managing Partner De Facto Communications
25 CHEMICALS KNOWLEDGE HUB Issue 2 / October 2025 ROUNDTABLE run-up to the event. This has two major benefits – you’ll reach new audiences and you’ll boost conversion rates of your existing contacts. For example, having respected media speak positively about your brand just as you’re meeting contacts is an incredibly powerful way to build trust quickly. When prospects read about you and you provide actual insights, not just fluff, and then meet you – or vice versa – it reinforces your credibility and leaves a lasting impression. For smaller biotech companies in particular, this can be the trust-building moment they need to feel confident about moving a project forward with a CDMO. Often, they aren’t aware of all the options available and you may well be approaching them as a ‘cold lead’, so building trust is everything. So, above all, focus on credibility not just selling. Show prospects that you put the same care into building your reputation and marketing communications, with insightful themes that help them rather than sell to them, as you will into nurturing their discovery project, IND filing, development or commercial delivery. Can you give a real-world example of making the news cycle work for your company and creating at show narratives? AH. Creating narratives and even news around industry trends – even when you don’t have ‘hard company news’ like a new site investment or acquisition – is an incredibly powerful way to deliver far-reaching news and insights. For example, last year much of the media conversation at CPHI focused on BIOSECURE. We looked at the implications of this and rather than letting it remain a WuXi-centric story, we reframed it with media to highlight Indian CDMOs as the key beneficiaries. The result was hundreds of pieces of coverage and a global conversation centred on our clients. Even better, this media campaign became a selfreinforcing business trend – many of our Indian clients have since publicly reported significant growth in discovery and more recently development contracts. In this case, we didn’t just ride the news cycle; we helped shape a new business strategy through our media outreach. We literally used the media to change outcomes for clients. If you could relive one CPHI moment, which would it be and why? AH. I’m going to throw my former colleague under the bus here – partly because it was hilarious in hindsight and partly because he has an absurdly long list of amusing CPHI anecdotes. In his defence, his eyesight isn’t the best (this is also the man who got stuck in Frankfurt’s Main Tower after being unable to spot the glass doors in the glass walls). So, we had just started working with the Indian Government and I was speaking with the Secretary of State for Health, who had flown in specially. Naturally, I was on my best behaviour. Suddenly, in he came – a whirlwind of energy – completely oblivious to who I was talking to, and in full Boris Johnson-esk fashion loudly declared that “we should be working with the Chinese government instead because they have more money!”. Not content with that, as I desperately tried to change the subject, he doubled down repeatedly…. before then vanishing faster than Keyser Söze. The whole exchange was so over-the-top that the Minister just turned to me and said, “You English are completely hilarious – I love Monty Python”. I nodded gingerly. But here’s the thing – that moment completely broke the ice. The rest of the evening turned into a genuinely open, collaborative conversation and we went on to build an incredibly strong partnership. The lesson? Sometimes letting your guard down – even by accident – is the fastest way to build trust. Did that experience influence how you prepared for future events or your networking style? AH. Strangely, it did, but not in the way you might expect. It reinforced the importance of preparation, but also taught me that once you’re on site at CPHI, all that prep is there to give you the freedom to be flexible and adaptive. It showed me the importance of a little personality because business partners trust you more when they connect with you as an individual. This slightly more relaxed version of myself means I get to really listen actively – so important when meeting new people – and gives the space need to develop deeper strategies. Of course, I now use all of Tristan’s hilarious stories as a constant source of ice-breaking material! What are any new comms trends you are seeing in pharma and at CPHI? AH. Easy question: short-form video content and news. This magazine, led by Ellie Bruni, has really led the charge, especially at CPHI, with her wide LinkedIn network and professional corporate video edits. If you haven’t done one, you should consider it. Inspired by Ellie, we’ve taken a different approach at De Facto to launch Biobeat – a weekly shortform video series re-reporting trade media news with analysis on TikTok. Why? Because TikTok
RkJQdWJsaXNoZXIy MjY2OTA4MA==